Dizal presents clinical updates of sunvozertinib for NSCLC patients

By Sakina Raj  | Date: 2022-08-06

Dizal presents clinical updates of sunvozertinib for NSCLC patients

Dizal Pharma has reportedly demonstrated supportive clinical updates for sunvozertinib,highlighting its therapeutic potential in NSCLC (non-small cell lung cancer) with EGFR Exon20ins (epidermal growth factor receptor exon 20 insertion) mutation.

This announcement was made at the 2022 WCLC (World Conference on Lung Cancer). It is worth noting that lung cancer is the world’s second-most common cancer and NSCLC represents around 85% of all lung cancers. Patients with EGFR Exon20ins mutated NSCLC lack effective treatment options.

Sunvozertinib is an oral, rationally designed, potent EGFR Exon20ins inhibitor. It was awarded Breakthrough Therapy Designation by China NMPA and U.S. FDA.

Currently, the inhibitor is being assessed in late-stage development in various globally crucial studies as the 1st line treatment for never treated patients and ≥ 2nd line treatment after the platinum-based chemotherapy.

The findings of the update were exhibited at the 2022 WCLC. As of April 30th, 2022, in platinum-pretreated patients, the best ORR evaluation at the 300mg QD RP2D was 52.4% as per the RECIST guidelines (version 1.1). In patients with standard brain metastasis, the best 300 mg QD ORR reached 44%.

Sunvozertinib’s safety profile was compliant with long-term treatment. The most common drug-associated treatment emergent adverse events (TEAE) were rash and diarrhea and most of them were Grade 1/2 and manageable clinically.

Dizal CEO, Dr. Xiaolin Zhang, has expressed that sunvozertinib’s favorable safety and antitumor efficacy make it capable of becoming a best-in-class treatment alternative for EGFR Exon20ins mutated NSCLC patients with persistently unmet medical needs.

The Shanghai-based biopharmaceutical company is committed to the discovery and development of evolved therapeutics for treating immunological diseases and cancer.

Deeply based on molecular design and translational science, it has formed a globally competitive portfolio of five assets in the clinical stage with two top assets in international pivotal studies.

Source credit:


About Author

Sakina Raj     aeresearch.net

Sakina Raj

Armed with a degree in English Literature, Sakina chose to explore the world of content writing and pursue it as a career. Sakina has been playing with words for over five years now and currently pens down articles relating to diverse domains for BonafideNews and vari...

Read More